OBJECTIVES: Left ventricular assist device (LVAD) implantation can be complicated by right ventricular (RV) failure. Several scores have been proposed to predict this event. Our aim was to validate three of these scores in a population which had received a rotary blood pump LVAD.
INTRODUCTION
Ventricular assist devices are an established therapy in heart failure as a bridge to transplant or destination therapy [1] . Despite the evolving technology and surgical experience, around 15% of patients who received left ventricular assist device (LVAD) experience right ventricular (RV) failure [2, 3] which leads to a worse survival, increased transfusion requirements and delayed or failed restoration of end-organ function [4] . Most of them necessitate prolonged inotropic support or right-sided mechanical devices. Several authors have demonstrated a higher rate of complication and poor results after biventricular support, especially when the right assist device was implanted in a delayed procedure [5] . Therefore, to predict which patients will benefit from an isolated LVAD or biventricular assist device (BIVAD) support could positively influence the perioperative morbidity and mortality. The complex pathophysiology of postoperative RV failure-RV myocardial dysfunction, ventricular interdependence and elevated RV afterload [6] -makes it difficult to predict this complication. Prognostic factors of RV failure were identified mostly by multivariate analysis [7, 8] , and predictive scores grouping multiple variables have been created to stratify the risk of BIVAD based on the preoperative information [9] [10] [11] . The scores are from a single institutional experience and were not validated in an external population to confirm their applicability.
The purpose of our study was to validate the accuracy of these scores predicting the need for right ventricular assist device (RVAD) in a population of patients undergoing LVAD implantation.
MATERIAL AND METHODS

Patients
The preoperative data of a consecutive series of 59 patients undergoing implantation of a full LVAD (HeartMate II or INCOR) were retrospectively reviewed and collected. The postoperative course was analysed and a periodical clinical follow-up was organized every month after the discharge. In the case of transplant, the patients regularly received a clinical, echocardiographic and invasive monitoring after 1 week and then at 1, 6 and 12 months.
From the clinical, echocardiographic, laboratory and haemodynamic records, we recalculated three scores predicting RVAD need in patients undergoing LVAD implantation.
Risk scores
The different risk scores were calculated from the following formulas:
Fitzpatrick's score = 18 (cardiac index, l/min) + 18 (RV stroke work index, mmHg l/m 2 ) + 17 (creatinine, mg/dl) + 16 ( previous cardiac surgery) + 16 (RV dysfunction) + 13 (systolic blood pressure, mmHg). Drakos' score = 3.5 (destination therapy) + 4 (intra-aortic balloon) + 4 ( pulmonary vascular resistance: 1 if PVR < 1. The best cut-off values to identify the need for RVAD were: for the Fitzpatrick's score ≥50, Drakos' score ≥12.5 and Matthews' score ≥5.5.
It was the institutional policy to implant an LVAD in all patients regardless of their risk score. RVADs were only considered if weaning from the cardiopulmonary bypass was not possible under moderate inotropic support. In the same period, patients with isolated left ventricular failure were included in a clinical study of partial support and are not included in the present study.
DATA ANALYSIS
The Mann-Whitney U-test scores were compared between the two groups; each score was then introduced in a univariate logistic regression analysis to assess the prediction of the need for BIVAD. To compare the performance of the scores, we evaluated their calibration and accuracy. The calibration was measured by the Hosmer-Lemeshow test, which determines whether or not the observed event rate matches the expected event rate in subgroups or deciles of the study population. The accuracy was expressed by the area under the curve (AUC) of the receiver operating characteristic (ROC) curve that reflects the relationship between sensitivity and specificity for a given test; the area measures the discrimination, defined as the ability of the test to correctly classify those with and without the disease; and an AUC of 0.5 reflects random forecasts, whereas an AUC of 1 implies perfect forecasts. In addition, from the number of predicted and observed events, we calculated the positive predictive value (PPV = true positive/true positive + false positive) and the negative predictive value (NPV = true negative/true negative + false negative).
All the preoperative variables were introduced in an exact logistic regression and a P-value of 0.05 was used to identify the significant predictors.
In the description of the data set, categorical and continuous variables were compared by the chi-squared and the unpaired t-tests. A Kaplan-Meier curve was used to represent the actuarial survival and a log-rank test to compare the survival distributions of two groups.
Statistical analysis was performed by R software, version 2.13 (The R Foundation for Statistical Computing, the Comprehensive R Archive Network).
RESULTS
The incidence of the need for RVAD was 23.7%. BIVAD support was required more commonly for female and younger patients and in the presence of non-ischaemic cardiomyopathy (Table 1) . (Tables 2 and 3) . We used two different devices for LV support: INCOR in 21 (35.59%) patients and HeartMate II in 38 (64.41%), implanted as a bridge to transplant (55 patients) and as destination therapy (4 patients). In patients with a temporary RV support, the most common device used was a centrifugal blood pump (n = 10), followed by ECMO (n = 2), Impella (n = 1) and pulsatile assist device (n = 1). The duration of LV support was 183.4 ± 174.2 days (max. 932 days) and for that of the RV support was 5.9 ± 3.2 days (max. 13 days).
The haemodynamic data before discharge from the ICU did not demonstrate any difference between an LVAD only and BIVAD in the cardiac output (5.68 ± 1.17 vs 6.03 ± 1.70 l/min, P = 0.62), systolic (32.2 ± 8.15 vs 30.5 ± 5.15 mmHg, P = 0.45) and diastolic pulmonary pressure (16.1 ± 6.80 vs 13.6 ± 5.50 mmHg, P = 0.25).
The actuarial survival did not differ between the two groups at 3 months (75.5%, SE = 0.02, vs 64.3%, SE = 0.07, P-value of 0.27) and at 1 year (54.4%, SE = 0.79, vs 64.3%, SE = 0.13, P-value of 0.91; Fig. 1 ). Patients supported with LVAD only died due to haemorhagic or embolic stroke (5 = 11.1%), bleeding (3 = 6.7%) and multiple organ failure (5 = 11.1%). Among these patients, three (6.7%) experienced an RV failure postoperatively. The patients with an additional RVAD died due to intraoperative dissection (1 = 7.1%) and haemorhagic or embolic stroke (4 = 28.6%).
Twenty-nine patients underwent a heart transplant (51.1% of the 'LVAD only' group and 42.8% of the BIVAD group, P-value of Analysing the absolute values of the scores, only the Fitzpatrick's score results are higher in the BIVAD, but without reaching a statistical significance (45.86 ± 14.02 in the BIVAD vs 42.1 ± 17.34 in the LVAD only, P = 0.12), whereas the other two scores were lower in the BIVAD group (Drakos: 4.57 ± 3.37 vs 4.94 ± 2.87, P = 0.51; Matthews: 2.71 ± 2.11 vs 2.92 ± 2.99, P = 0.97). They were not predictive of RVAD support from the logistic regression analysis and the ROC AUC varied from 50 to 63.4%. The three scores demonstrated a low calibration with a significant P-value of the HosmerLemeshow test. The Fitzpatrick and Drakos' scores demonstrated a high rate of false positive with a low PPV; contrarily the Matthews' score reached a low NPV ( Table 4) .
The exact logistic regression individualized the non-ischaemic aetiology (P < 0.05) as significant risk factors for BIVAD support.
DISCUSSION
The validation of the three previously published scores to predict the need of RV assist after LVAD implantation demonstrated a poor calibration and accuracy. The logistic regression analysis showed the inefficacy of the scores to predict the outcome, the accuracy of the model was close to a random classification (random = 0.5 of the AUC of the ROC) [12] and the Hosmer-Lemeshow test reported a significant difference between the expected and observed events in the deciles of the study groups [12, 13] . From these findings, we could conclude that the three scores applied in different populations could not be considered a valid prognostic tool.
In the last decades, scoring systems have been extensively used in cardiac surgery, especially in the USA and Europe [14] [15] [16] , with the intention of stratifying the mortality risk individually. These instruments were applied in the comparison of risk-adjusted outcomes, evaluating care programmes, institutions or personal results. Such analysis could confirm positively or negatively the performance of a surgical unit, with tremendous medical and financial consequences. Many validation studies have been conducted on the cardiovascular scoring systems and several of them have also been demonstrated to be inefficacious after external validation [17] . EuroSCORE overestimates the 1-month mortality risk [18, 19] . It was created from a multicentre population of 17 000 patients collected between 1993 and 1996. In the last decade, the profile of the cardiac surgery population has radically changed, with more older and sicker patients coming to surgery than before, and it is plausible that the original EuroSCORE population no longer reflects the actual risk profile [20] .
A discrepancy between the patient's group used to build the scores and the validation group is a likely explanation for the shortcoming. In our study, in fact, the distribution of the risk factors used to build the scores differs from the ones of the validation group. Fitzpatrick in his scoring system [9] used five variables: cardiac output, pulmonary vascular resistance, preoperative creatinine level, RV dysfunction and previous cardiac surgery, of which only the first two are significantly predictive of a BIVAD in our study. In Drakos' work [11] , 42% of the patients received an LVAD as destination therapy, whereas in our group, this was only 6.78%; the percentage of obese patients was higher in the BIVAD group (34 vs 23%), whereas in our experience, it was higher in the LVAD only group (but not significantly). Also the need of preoperative ventilation support and counterpulsation (43 vs 26% and 49 vs 31%) were other predictors in the score, but were excluded from our analysis. None of the included risk factors of the Matthews' prediction system were identified in our study as prognostic for the need for an RVAD.
We analysed a highly mixed population: the presenting clinical status can vary from patients in acute shock to haemodynamically stable patients without any inotropic support, and ages can range from paediatric to adult; therefore, the possible application of the scores becomes very challenging; we could not expect that a score created only on laboratory data and vasopressor requirement [10] to describe a specific outcome in a population where no differences for these parameters were registered. The variability could be decreased, analysing larger multicentre data sets and unifying experiences coming from several countries.
From the multivariate analysis, we found that the presence of non-ischaemic etiology (corresponding to the presence of dilated cardiomyopathy) was the major predictor for RV failure. These patients experienced a leftward shift of the septum and a loss of interventricular balance increasing the RV compliance and decreasing the RV contractility [21] . In the case of normal structure and preoperative RV function, most of the patients can compensate for this phase, but in the case of a structural biventricular dysfunction, as in the presence of dilated cardiomyopathy, the possibilities of RV compensation are minimal [22, 23] . Our findings confirmed the results published by Farrar [4] in his Thoratec experience with a higher proportion of the biventricular assistance in the presence of dilated cardiomyopathy (46%) rather than ischaemic cardiomyopathy (40%). Furthermore, Iskandrian et al. [24] reported that RV ejection fraction was higher and the RV end-diastolic volume/LV end-diastolic volume ratio by multigated radionuclide angiography was lower in 69 patients with ischaemic cardiomyopathy than in 21 patients with primary cardiomyopathy, suggesting a preserved RV performance in ischaemic cardiomyopathy.
The examination of the PPV and NPV shows that between 22 and 36 patients were incorrectly allocated (sum of false positive and false negative per score); in our model, this number decreases to 12.
In conclusion, the RV failure scores had no predictive value in our patient population. The use of the scores poses the risk of selecting patients for a BIVAD, when they do not need it and vice versa.
A multifactorial analysis remains the standard method in the investigation of possible interactions between the need for RVAD and its predictors.
Our work contains some limitations. The number of patients is small; we wanted to include only patients treated with a rotary blood pump and not a pulsatile device. The results we obtained might have been influenced and be a consequence of the insufficient number of patients. This is a common limitation in this field, because the cases per year remain limited in the most centres. The collection of new data from other patients and the analysis of a multicenter data set could reduce this lack of information and mitigate the variability of the study population.
Second, in our study, we experienced a relatively high rate of RV failure. A possible explanation could be the trial we conducted during the study period to test the Circulite assist device. Patients with a low-risk profile were included in the trial and thus excluded from the present series. In total, we implanted, during the study period, 20 patients with this device and none of them experienced RV failure. With the inclusion of these patients, our RV failure rate diminishes from 23.7 to 17.7%. Third, the definition of RV failure was limited to patients treated with an RVAD. This could leave out patients who experienced RV failure, but in whom the diagnosis was missed or who did not require an RVAD.
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